Intellia Therapeutics Ownership | Who Owns Intellia Therapeutics?
Intellia Therapeutics Ownership Summary
Intellia Therapeutics is owned by 92.18% institutional investors, 1.21% insiders, and 6.61% retail investors. Ark investment management is the largest institutional shareholder, holding 12.41% of NTLA shares. ARK Innovation ETF is the top mutual fund, with 8.59% of its assets in Intellia Therapeutics shares.
NTLA Ownership Benchmark
Type | Name | % Inst | % Insiders | % Retail |
---|---|---|---|---|
Stock | Intellia Therapeutics | 92.18% | 1.21% | 6.61% |
Sector | Healthcare Stocks | 88.01% | 8.90% | 3.09% |
Industry | Biotech Stocks | 109.70% | 8.77% | -18.47% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
Holder | Shares | % Holding | Value |
---|---|---|---|
Ark investment management | 12.54M | 12.41% | $146.17M |
Blackrock funding, inc. /de | 10.86M | 10.75% | $126.60M |
Blackrock | 9.60M | 10.05% | $214.79M |
Vanguard group | 9.10M | 9.53% | $203.66M |
Deep track capital, lp | 4.80M | 5.03% | $107.42M |
State street | 4.36M | 4.57% | $97.64M |
Regeneron pharmaceuticals | 3.70M | 3.67% | $43.18M |
Nikko asset management americas | 2.99M | 2.96% | $34.89M |
Sumitomo mitsui trust | 2.99M | 2.96% | $34.89M |
Morgan stanley | 2.34M | 2.45% | $52.32M |
Top Institutional Shareholders by % of Total Assets
Holder | Shares | % Assets | Value |
---|---|---|---|
Discovery value fund | 561.56K | 6.39% | $12.57M |
Regeneron pharmaceuticals | 3.70M | 3.94% | $43.18M |
Deep track capital, lp | 4.80M | 3.21% | $107.42M |
Contrarius investment management | 1.92M | 2.68% | $42.87M |
Himension capital (singapore) pte. | 1.03M | 1.63% | $23.05M |
Bioimpact capital | 443.50K | 1.54% | $9.93M |
Ark investment management | 12.54M | 1.22% | $146.17M |
Orchard capital management | 170.01K | 1.15% | $3.80M |
Evolutionary tree capital management | 36.26K | 0.84% | $811.54K |
Pdt partners | 227.22K | 0.48% | $5.09M |
Top Buyers
Holder | Shares | % Assets | Change |
---|---|---|---|
Regeneron pharmaceuticals | 3.70M | 3.94% | 3.70M |
Blackrock funding, inc. /de | 10.86M | 0.00% | 1.08M |
Deep track capital, lp | 4.80M | 3.21% | 589.22K |
Contrarius investment management | 1.92M | 2.68% | 564.88K |
Blackrock | 9.60M | 0.00% | 488.34K |
Top Sellers
Holder | Shares | % Assets | Change |
---|---|---|---|
Wellington management group llp | 781.77K | 0.00% | -3.38M |
Rokos capital management llp | - | - | -1.14M |
Chevy chase trust | 288.32K | 0.01% | -522.71K |
Price t rowe associates inc /md/ | 1.24M | 0.00% | -380.09K |
Voloridge investment management | 452.45K | 0.04% | -343.07K |
New Positions
Holder | Shares | % Assets | Change | Value |
---|---|---|---|---|
Regeneron pharmaceuticals | 3.70M | 3.94% | 3.70M | $43.18M |
Raymond james financial | 411.08K | 0.00% | 411.08K | $4.79M |
Norges bank | 240.41K | 0.00% | 240.41K | $5.38M |
Mirae asset global etfs | 234.81K | 0.01% | 234.81K | $5.26M |
Sphera funds management | 139.42K | 0.43% | 139.42K | $3.12M |
Sold Out
Holder | Change |
---|---|
Dinuzzo private wealth | -1.00 |
Jfs wealth advisors | -2.00 |
Baldwin brothers llc/ma | -4.00 |
Family firm | -15.00 |
Nelson, van denburg & campbell wealth management group | -17.00 |
Institutional Ownership Trends
Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
---|---|---|---|---|---|---|---|---|---|---|
Sep 30, 2024 | 290 | -5.54% | 93,104,860 | 3.35% | 92 | 1.07% | 150 | -7.41% | 84 | -4.55% |
Jun 30, 2024 | 302 | 0.67% | 90,028,919 | -0.69% | 94 | 1.05% | 160 | 5.26% | 86 | -2.27% |
Mar 31, 2024 | 300 | -2.28% | 90,656,601 | 6.41% | 94 | 1.03% | 152 | -11.11% | 88 | 10.00% |
Dec 31, 2023 | 307 | 4.07% | 85,199,452 | 6.57% | 95 | 1.18% | 171 | 14.77% | 80 | 19.40% |
Sep 30, 2023 | 295 | -1.67% | 79,946,745 | 2.21% | 90 | 1.15% | 149 | 7.97% | 67 | -11.84% |
Top Mutual Funds Shareholders
Holder | Shares | % Holding | Change |
---|---|---|---|
ARK Innovation ETF | 8.75M | 8.59% | 28.34K |
ARK Disruptive Innovation Full Composite | 8.62M | 8.47% | 343.37K |
Vanguard Total Stock Mkt Idx Inv | 3.04M | 2.99% | 4.16K |
ARK Genomic Revolution ETF | 2.97M | 2.91% | - |
ARK Genomic Revolution | 2.86M | 2.81% | -212.45K |
iShares Russell 2000 ETF | 2.76M | 2.71% | -21.00K |
SPDR® S&P Biotech ETF | 2.75M | 2.70% | -26.75K |
Vanguard Small Cap Index | 2.46M | 2.42% | 33.35K |
Nikko AM ARK Disruptive Innovation A USD | 1.95M | 1.92% | -45.23K |
Vanguard Institutional Extnd Mkt Idx Tr | 1.62M | 1.59% | 95.00K |
Recent Insider Transactions
Date | Name | Role | Activity | Value |
---|---|---|---|---|
Jan 29, 2025 | Bhanji Muna | - | Sell | $2.64K |
Jan 03, 2025 | Dube Michael P | VP, Chief Accounting Officer | Sell | $16.71K |
Jan 03, 2025 | BASTA JAMES | EVP, General Counsel | Sell | $86.16K |
Jan 03, 2025 | Lebwohl David | EVP, Chief Medical Officer | Sell | $116.40K |
Jan 03, 2025 | Hicks Derek | EVP, Chief Business Officer | Sell | $79.19K |
Insider Transactions Trends
Date | Buy | Sell |
---|---|---|
2025 Q1 | - | 9 |
2024 Q4 | - | 1 |
2024 Q3 | - | 1 |
2024 Q2 | - | 1 |
2024 Q1 | - | 12 |
NTLA Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools